Ginkgo Bioworks (DNA) vs Tectonic Therapeutic (TECX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Tectonic Therapeutic (TECX) has outperformed Ginkgo Bioworks (DNA) over the past year, gaining 8.1% versus a loss of 8.7%. Over five years, TECX leads with a -57.7% price change compared with -98.5% for DNA. Ginkgo Bioworks is the larger company by market cap ($483.5 million vs $405.3 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DNA | TECX |
|---|---|---|
| Share price | $7.46 | $20.73 |
| Market cap | $483.54M | $405.26M |
| 1-day change | -9.02% | -1.47% |
| YTD return | -10.23% | -0.62% |
| 1-year return | -8.69% | +8.08% |
| 5-year return | -98.45% | -57.66% |
| EPS (TTM) | $-4.24 | $-4.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $170.16M | — |
| Revenue growth (YoY) | -25.06% | — |
| Net income (latest FY) | $-312.76M | $-74.15M |
| Operating margin | -185.29% | — |
| Net margin | -183.81% | — |
| 52-week high | $18.22 | $39.53 |
| 52-week low | $5.37 | $16.77 |
| Distance from 52-week high | -59.06% | -47.56% |
| Analyst consensus | underperform | strong_buy |
| Avg. price target upside | +7.24% | +242.50% |
| Average volume | 2.53M | 212.16K |
| Shares outstanding | 53.94M | 19.55M |
| Employees | 485 | 60 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TECX has outperformed DNA by 16.8 percentage points over the past year.
About Ginkgo Bioworks
DNA stock →Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 485 employees
About Tectonic Therapeutic
TECX stock →Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 60 employees
DNA vs TECX FAQ
Which is bigger, Ginkgo Bioworks or Tectonic Therapeutic?
Ginkgo Bioworks (DNA) is larger, with a market capitalization of $483.54M compared with $405.26M for Tectonic Therapeutic (TECX).
Which stock has performed better over the past year, DNA or TECX?
TECX returned +8.08% over the past 12 months, compared with -8.69% for DNA (price return, excluding dividends). Past performance does not predict future results.
Are Ginkgo Bioworks and Tectonic Therapeutic in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.